DAILY OUTLOOK
MONEYGUYMUTANTS
Daily Outlook

Hawkish minutes and a Medicare audit rule sink the Dow, not Nvidia

The S&P 500 slipped 0.23% for a fifth straight loss and the Dow fell 561 points as UnitedHealth dropped 10% on a CMS audit proposal and Fed minutes leaned toward more hikes. Nvidia's beat faded to a 2.9% loss. The variant view: the pressure has moved from AI to policy (rates and regulation), and that kind is harder to trade around.

Educational market commentary, not investment advice. Nothing here is a recommendation to buy or sell any security.

NVDAUNHHUMTJXTGTSPY#healthcare#semiconductors#consumer

Research and idea generation for personal use. Not investment advice. See full disclaimer at the bottom.

Top of mind

Prepared before the open on Thursday, November 19, so the latest complete session is Wednesday, November 18. The S&P 500 fell 0.23% to 7,323.63, its fifth straight loss, and the Dow dropped 561.25 points. The drag was UnitedHealth, down about 10% on a proposed Medicare Advantage audit rule, together with Fed minutes showing most officials expect more hikes. Nvidia beat on revenue and still closed down 2.9%, so for a second day the selling was driven by policy, not AI.

Market snapshot

Wednesday, November 18 close. Index levels and changes come from Yahoo Finance and Stock Titan's closing recaps. Direction matches 24/7 Wall St, the Reuters wrap carried by NST, and FN News. Each level also equals Tuesday's close plus the reported point change.

Asset Level Change Notes
S&P 500 7,323.63 -0.23% (-16.90) Fifth straight loss; longest losing streak since June
Nasdaq Composite 24,429.88 +0.42% (+101.50) Snapped its losing streak despite Nvidia's drop
Dow Jones 50,198.17 -1.11% (-561.25) Three-month low; UnitedHealth was the largest drag
10Y Treasury about 5.07–5.11% flat to about -4 bps Sources disagree on the level; still above 5%
VIX 24.52 -3.7% Single source; down from Tuesday's 25.46

Read-through: The index moves were small, but the gap underneath was large: about 1.3 percentage points between the Dow and the Nasdaq. Selling moved from software into managed care, and long Treasuries again did little to offset it. When one regulatory proposal can take 10% off a top Dow component, and the Fed minutes argue for more hikes, the risks come from policy and are harder to hedge than an earnings miss.

Headlines & analysis

1. Fed minutes: almost all officials see more hikes as likely

Source: Fed minutes as reported by KuCoin News and HDFC Sky market recaps; NST/Reuters wrap So what: Minutes from the October 27–28 meeting, which left the target range at 3.75%–4%, reportedly showed that nearly all participants expect further increases to be appropriate under their baseline outlook. Two members (Cook and Hammack) dissented in favor of hiking at that meeting. A quarter-point hike on December 8–9 was already close to fully priced, so the minutes matter less for December and more for whether hikes continue into 2027. That is a headwind for long-duration stocks and bonds alike.

2. UnitedHealth falls 10% and Humana 13% on CMS's "CRUSH" audit proposal

Source: Gotrade, Stock Titan, BigGo Finance, Quantisnow So what: UnitedHealth closed down 10.21% at $349.91, and Humana fell 12.98% to $385.78, the S&P 500's worst performer. Elevance fell about 7.6%, and reports of CVS's decline range from 3% to 5%. The proposed rule would widen Medicare Advantage risk-adjustment audits and apply sampled error rates across whole contracts going back to payment year 2018. CMS estimates the savings at about $90 billion over ten years. UnitedHealth has not said how much it could owe. Comments close January 19, 2027, so the rule can still change. One TIKR report dates the first move to Monday at about 5%, which suggests the selling built over several sessions.

3. Nvidia beats and closes down 2.9%

Source: Motley Fool, CNBC, Techi, Yahoo Finance So what: Nvidia closed at $150.96, down 2.89%, after rising almost 4% before the open. Revenue of $115.84 billion and a fourth-quarter guide of $130 billion both beat LSEG consensus ($109.1 billion and $125.1 billion). What weighed on the stock was the 71–72% gross-margin guide, down from 74.8%, China being excluded from the outlook, and the chair confirming that Huang will not return as CEO, with no timeline for a successor. Techi counts nine of the last ten reports where the stock closed below its post-report open. CNBC says the drop also pulled down CoreWeave and Iren.

4. Off-price retail wins: TJX raises its outlook, Target rises, Lowe's barely moves

Source: CNBC Investing Club, Business of Fashion/Reuters, Quartz, Finimize So what: TJX raised its full-year adjusted EPS outlook to $5.17–$5.20 from $5.15–$5.20 and guided fourth-quarter comparable sales up 2–3%. Reports of the stock's gain range from about 5% to more than 8%, depending on the time of the quote. Target reportedly rose about 4–4.5% after comparable sales beat (thinly sourced). Lowe's beat on EPS, but its gross margin shrank on fuel and freight costs, and the stock rose less than 1%. Coverage attributes TJX's strength to shoppers moving to off-price chains as inflation and fuel costs squeeze budgets. Spending is holding up but moving to cheaper stores.

5. Anthropic prices its IPO at $83, above the range; ANT trades today

Source: Yahoo Finance live blog, Motley Fool (citing Reuters, Bloomberg and CNBC sources), Stock Titan So what: The reported price is $83 against a $70–$78 range on 825 million shares. Fool estimates the fully diluted valuation at about $1.5 trillion. Reports of the total raise conflict because of the separate private placement. No view is offered on the offering. For existing holdings, the question is whether the software selling tied to the deal eases now that pricing is done. (Disclosure: this report was drafted with an AI model built by Anthropic.)

Ideas — long-term core

Quality businesses, durable competitive advantages, reasonable valuation. Hold horizon: years.

UNH — UnitedHealth Group (watch, not yet)

  • Thesis: UnitedHealth is the largest U.S. managed-care company and has one of the biggest care-delivery and data businesses alongside it. When a large company falls 10% on a proposed rule, a long-term investor should look at it, because proposals are often softened during the comment period.
  • Valuation note: I could not confirm a current, dated P/E or free-cash-flow yield, so no valuation case is made here. Do that work before you take a view.
  • Why now (or why patient): Be patient. The rule's financial impact has not been quantified, the comment window runs to January 19, 2027, and the selling has gone on for more than one session. Waiting for UnitedHealth to put a number on its exposure costs little.
  • Risks / bear case: The clawback reaches back to 2018 and applies sampled error rates to entire contracts. If it is finalized largely as proposed, the liability could be large and could reset margin expectations. That matters most for the companies that rely most on Medicare Advantage, and Humana's sharper drop reflects that.

No other long-term idea today. Broad index investors adding on a schedule have no reason in this tape to stop. Bear case for adding now: the 10-year is above 5%, the minutes point to more than one more hike, and the S&P 500 has fallen five days in a row.

Ideas — opportunistic

Catalyst-driven, time-bound, sized smaller. Hold horizon: days to months. Define exit before entry.

NVDA — Yesterday's test failed; step aside

  • Catalyst: Wednesday's post set a rule: a close below Monday's $156.14 meant the post-earnings setup had failed. Nvidia closed at $150.96, so it failed. This is a follow-up, not a new trade.
  • Time horizon: Re-assess after a CEO successor timeline or new export-rule clarity.
  • What would invalidate (the stand-aside view): A close back above $156.14 on heavy volume, or a named permanent CEO. Either would answer the main open question.
  • Risk note: The stock is down more than 13% in a week and could bounce sharply on a single headline. Chasing a bounce without a defined level is not a setup.

UNH / HUM — Comment-period overreaction or a fair reset?

  • Catalyst: Company statements quantifying exposure, analyst estimate revisions, and the January 19, 2027 comment deadline.
  • Time horizon: Weeks to two months.
  • What would invalidate: A new low below Wednesday's closes ($349.91 for UNH, $385.78 for HUM) after a company quantifies its exposure. That would mean the number was worse than feared.
  • Risk note: Policy-driven stocks can gap on a single headline, in either direction. Keep positions small and decide your exit before you enter.

Portfolio-level guidance

Allocation and risk observations. Not specific buy/sell calls — those depend on a full picture this report doesn't see.

  • Concentration check: The selling has moved from chips to software to managed care in three sessions. Diversifying across sectors helps less when the common cause is rates and regulation. Check how much of your portfolio depends on government reimbursement or the policy-rate path, not just on one sector.
  • Rates positioning: The minutes lean toward more hikes, and the 10-year stays above 5%. Long Treasuries have not hedged stock declines this week. Short-duration Treasuries and cash still pay well without that risk.
  • Cash & dry powder: Five straight losses for the S&P 500 is uncomfortable but not unusual. If you deploy cash on a schedule, keep to the schedule rather than trying to time a bottom.
  • Risk regime read: The VIX eased to about 24.5 (single source) while the Dow fell more than 1%. Investors paid less for protection even as the losses broadened. A move back toward 30 would mean real stress. Holding in the low 20s would suggest a market that is rotating, not panicking.

Watch list — tomorrow / this week

Earnings: Walmart before the open today (Thursday), along with Alibaba and NetEase per earlier calendars. Walmart's commentary on the low-income shopper is the test of the shift to off-price stores that TJX's results showed. Economic data: I could not confirm today's release schedule or consensus figures, so none are listed. Fed / central bank: Watch Fed speakers responding to the minutes. The December 8–9 FOMC is close to fully priced for a quarter-point hike. Other: Anthropic (ANT) first trade on Nasdaq today. Any UnitedHealth or Humana statement on CRUSH exposure. Risks to this call: the VIX close and Target's move each rest on a single source, the 10-year level varies by about 4 bps across outlets, and commodities and the dollar could not be confirmed for Wednesday and are omitted. An obvious risk is a sixth straight S&P 500 loss if ANT's debut pulls money from other tech holdings. A less obvious one is that health care keeps falling even after its exposure is quantified, which would show the market is pricing policy risk across sectors and not only in AI.

Disclaimer

This report is prepared for personal research and informational purposes only. It does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Information is drawn from public sources believed to be reliable but is not guaranteed accurate or complete. Markets change rapidly; data may be stale by the time of reading. Any "ideas" mentioned are research candidates, not recommendations, and do not consider any specific person's financial situation, objectives, or risk tolerance. Consult a licensed financial advisor before making investment decisions. Past performance does not predict future results.

GET THIS BY EMAIL

Wake up to the outlook.

Free. Weekday mornings + a Sunday recap. Unsubscribe in one click.

Free. Every weekday morning. Unsubscribe in one click.

More from Money Guy Mutants Research

Browse all outlooks.

View the archive